BACKGROUND: Disease Management Programmes (DMPs) are successful in reducing hospital readmissions in heart failure (HF). However, there remain a number of patients enrolled in a DMP who are readmitted with HF. The primary aim of the study was to determine the proportion of preventable readmissions (PR). The secondary aim was to recognise patient characteristics which would identify certain patients at risk of having a PR. METHODS: A retrospective chart search was performed on patients readmitted over a 1-year period. RESULTS: 38.5% of readmissions were classified as PR. None of these patients made prior contact with the DMP. Admission levels of BNP, potassium, urea and creatinine were significantly lower in the PR group. CONCLUSION: DMP have proven benefits in reducing hospital readmission nonetheless a significant proportion of these readmissions are preventable. Further work is required to prospectively analyse why these patients fail to contact the DMP.
BACKGROUND: Disease Management Programmes (DMPs) are successful in reducing hospital readmissions in heart failure (HF). However, there remain a number of patients enrolled in a DMP who are readmitted with HF. The primary aim of the study was to determine the proportion of preventable readmissions (PR). The secondary aim was to recognise patient characteristics which would identify certain patients at risk of having a PR. METHODS: A retrospective chart search was performed on patients readmitted over a 1-year period. RESULTS: 38.5% of readmissions were classified as PR. None of these patients made prior contact with the DMP. Admission levels of BNP, potassium, urea and creatinine were significantly lower in the PR group. CONCLUSION:DMP have proven benefits in reducing hospital readmission nonetheless a significant proportion of these readmissions are preventable. Further work is required to prospectively analyse why these patients fail to contact the DMP.
Authors: Jean-Pierre Bassand; Christian W Hamm; Diego Ardissino; Eric Boersma; Andrzej Budaj; Francisco Fernández-Avilés; Keith A A Fox; David Hasdai; E Magnus Ohman; Lars Wallentin; William Wijns Journal: Eur Heart J Date: 2007-06-14 Impact factor: 29.983
Authors: K MacIntyre; S Capewell; S Stewart; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; J J McMurray Journal: Circulation Date: 2000-09-05 Impact factor: 29.690
Authors: M Komajda; F Follath; K Swedberg; J Cleland; J C Aguilar; A Cohen-Solal; R Dietz; A Gavazzi; W H Van Gilst; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; J Widimsky; N Freemantle; J Eastaugh; J Mason Journal: Eur Heart J Date: 2003-03 Impact factor: 29.983
Authors: Mark Ledwidge; Michael Barry; John Cahill; Enda Ryan; Brian Maurer; Mary Ryder; Bronagh Travers; Lorna Timmons; Ken McDonald Journal: Eur J Heart Fail Date: 2003-06 Impact factor: 15.534
Authors: Anna T Mathew; Lisa Rosen; Renee Pekmezaris; Andrzej Kozikowski; Daniel W Ross; Thomas McGinn; Kamyar Kalantar-Zadeh; Steven Fishbane Journal: Kidney Int Rep Date: 2017-11-03
Authors: Emily Seto; Heather Ross; Alana Tibbles; Steven Wong; Patrick Ware; Edward Etchells; Jeremy Kobulnik; Tamanna Chibber; Stephanie Poon Journal: JMIR Res Protoc Date: 2020-01-22